174 related articles for article (PubMed ID: 22174377)
21. Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen.
Watters RJ; Hartmaier RJ; Osmanbeyoglu HU; Gillihan RM; Rae JM; Liao L; Chen K; Li W; Lu X; Oesterreich S
Mol Cell Endocrinol; 2017 Jun; 448():21-27. PubMed ID: 28286232
[TBL] [Abstract][Full Text] [Related]
22. Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity.
Martini PG; Delage-Mourroux R; Kraichely DM; Katzenellenbogen BS
Mol Cell Biol; 2000 Sep; 20(17):6224-32. PubMed ID: 10938099
[TBL] [Abstract][Full Text] [Related]
23. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
Karmakar S; Foster EA; Blackmore JK; Smith CL
Endocr Relat Cancer; 2011 Feb; 18(1):113-27. PubMed ID: 21059860
[TBL] [Abstract][Full Text] [Related]
24. Coactivators PGC-1beta and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen.
Kressler D; Hock MB; Kralli A
J Biol Chem; 2007 Sep; 282(37):26897-26907. PubMed ID: 17631495
[TBL] [Abstract][Full Text] [Related]
25. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
26. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
27. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
[TBL] [Abstract][Full Text] [Related]
29. Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells.
Wu J; Williams D; Walter GA; Thompson WE; Sidell N
Exp Cell Res; 2014 Nov; 328(2):351-60. PubMed ID: 25172557
[TBL] [Abstract][Full Text] [Related]
30. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains.
Métivier R; Penot G; Flouriot G; Pakdel F
Mol Endocrinol; 2001 Nov; 15(11):1953-70. PubMed ID: 11682626
[TBL] [Abstract][Full Text] [Related]
31. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
33. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
34. Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Elsberger B; Paravasthu DM; Tovey SM; Edwards J
J Cancer Res Clin Oncol; 2012 Feb; 138(2):327-32. PubMed ID: 22134837
[TBL] [Abstract][Full Text] [Related]
35. Endogenous estrogen levels, bone mineral density and estrogen receptor status in breast cancer.
Altundag K; Altundag O; Gunduz M
Breast Cancer Res Treat; 2005 Jan; 89(2):213. PubMed ID: 15692765
[No Abstract] [Full Text] [Related]
36. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
37. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
39. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
40. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.
Kojetin DJ; Burris TP; Jensen EV; Khan SA
Endocr Relat Cancer; 2008 Dec; 15(4):851-70. PubMed ID: 18755852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
